Dec. 21, 2024 – Dec. 31, 2024 • New York, NY, USA, New York ...
The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...
DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.
An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...
The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...
While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback